While a fair amount of clinical data on Stargardt disease type 1 (STGD1) have been published,
very little is known about Stargardt disease type 4 (STGD4). The ProgStar 04 study is an
important opportunity to leverage the infrastructure, clinical trials sites, methods, and
central reading center of the ProgStar program to investigate the progression of STGD4 and
will help to establish patient cohorts worldwide for future clinical trials.